BELINOSTAT酰胺 | 1485081-57-9

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 中文名称: BELINOSTAT酰胺
• 英文名称: Belinostat amide
• 英文别名: (E)-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide
• CAS: 1485081-57-9
• 化学式: C₁₅H₁₄N₂O₃S
• 分子量: 302.4
• InChiKey: LUVPQDAKKRMIOY-MDZDMXLPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  21
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  97.6
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• [EN] SOLID STATE FORMS OF (2E)-N-HYDROXY-3-[3-(PHENYLSULFAMOYL)PHENYL]PROP-2-ENAMIDE AND PROCESS FOR PREPARATION THEREOF<br/>[FR] FORMES À L'ÉTAT SOLIDE DE (2E)-N-HYDROXY-3-[3- (PHÉNYLSULFAMOYL) PHÉNYL] PROP-2-ÉNAMIDE ET LEUR PROCÉDÉ DE PRÉPARATION
  申请人：MSN RES & DEVELOPMENT CENTER

  公开号：WO2018029699A1

  公开（公告）日：2018-02-15

  The Present invention relates to solid state forms of (2E)-N-hydroxy-3-[3-(N-phenyl sulfamoyl)phenyl]prop-2-enamide represented by the following structural formula-1 and process for the preparation thereof.

  本发明涉及以下结构式-1所代表的（2E）-N-羟基-3-[3-(N-苯磺酰基)苯基]丙-2-烯酰胺的固态形式以及其制备方法。
• COMBINED USE OF PRAME INHIBITORS AND HDAC INHIBITORS
  申请人：Vereniging Het Nederlands Kanker Instituut

  公开号：EP1711210A2

  公开（公告）日：2006-10-18
• METHODS OF TREATMENT EMPLOYING PROLONGED CONTINUOUS INFUSION OF BELINOSTAT
  申请人：Topotarget A/S

  公开号：EP2262493A1

  公开（公告）日：2010-12-22
• [EN] COMBINED USE OF PRAME INHIBITORS AND HDAC INHIBITORS<br/>[FR] UTILISATION COMBINEE D'INHIBTEURS DE PRAME ET DE HDAC
  申请人：VERENIGING HET NL KANKER I

  公开号：WO2005074995A2

  公开（公告）日：2005-08-18

  The invention relates to the cancer antigen PRAME (PReferentially expressed Antigen in MElanoma) and its use in a method of treatment of a tumour which comprises administering to a subject in need of treatment an effective amount of an inhibitor of PRAME, in combination with a second agent selected from the group of an inhibitor of HDAC (an HDACi) and a retinoid.
• [EN] METHODS OF TREATMENT EMPLOYING PROLONGED CONTINUOUS INFUSION OF BELINOSTAT<br/>[FR] PROCÉDÉS DE TRAITEMENT EMPLOYANT UNE PERFUSION CONTINUE PROLONGÉE DE BELINOSTAT
  申请人：TOPOTARGET AS

  公开号：WO2009109861A1

  公开（公告）日：2009-09-11

  The present invention relates generally to the treatment of diseases and disorders that are mediated by histone deacetylase (HDAC), for example, cancer, with BelinostatTM (also known as (E)-N-hydroxy-3-(3-phenylsulfamoyl-phenyl)-acrylamide; PXD101; and PX 105684), and more particularly, to improvement treatments of such diseases (for example, cancers, for example, leukemias), which employ prolonged continuous infusion (e.g., prolonged continuous intravenous infusion) of BelinostatTM.